ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 300 filers reported holding ACADIA PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 1.07 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $340,067 | +728.6% | 16,318 | +533.0% | 0.00% | – |
Q4 2022 | $41,042 | -71.9% | 2,578 | -75.2% | 0.00% | – |
Q2 2022 | $146,000 | -92.7% | 10,390 | -87.9% | 0.00% | -100.0% |
Q4 2021 | $2,000,000 | -6.6% | 85,687 | -33.6% | 0.01% | -22.2% |
Q3 2021 | $2,142,000 | -76.2% | 128,978 | -40.8% | 0.01% | -86.4% |
Q3 2020 | $8,987,000 | +2277.5% | 217,864 | +2696.0% | 0.07% | +2100.0% |
Q2 2020 | $378,000 | -70.4% | 7,792 | -90.1% | 0.00% | -66.7% |
Q4 2018 | $1,275,000 | -95.3% | 78,845 | -94.0% | 0.01% | -92.6% |
Q3 2018 | $26,907,000 | +29.7% | 1,311,076 | -3.5% | 0.12% | +29.8% |
Q2 2018 | $20,749,000 | +27.5% | 1,358,793 | +87.5% | 0.09% | +38.2% |
Q1 2018 | $16,280,000 | +51.0% | 724,500 | +102.4% | 0.07% | +100.0% |
Q4 2017 | $10,778,000 | +32.5% | 357,958 | +22.7% | 0.03% | +3.0% |
Q2 2017 | $8,137,000 | -34.8% | 291,745 | -32.6% | 0.03% | -50.7% |
Q4 2016 | $12,479,000 | +4356.8% | 432,691 | +4226.9% | 0.07% | +3250.0% |
Q1 2016 | $280,000 | – | 10,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
March Altus Capital Management LP | 82,723 | $2,685,000 | 20.75% |
HWG Holdings LP | 289,380 | $9,393,000 | 8.72% |
Baker Brothers Advisors | 24,516,738 | $795,813,000 | 8.34% |
HARVEY CAPITAL MANAGEMENT INC | 352,200 | $11,432,000 | 5.73% |
Belmont Global Advisors, Inc. | 150,000 | $4,869,000 | 4.67% |
Palo Alto Investors LP | 1,437,730 | $46,669,000 | 3.52% |
Avoro Capital Advisors LLC | 329,500 | $10,696,000 | 2.38% |
GARRISON BRADFORD & ASSOCIATES INC | 70,100 | $2,275,000 | 2.23% |
WEATHERBIE CAPITAL, LLC | 401,642 | $13,037,000 | 1.85% |
ACUTA CAPITAL PARTNERS, LLC | 85,999 | $2,792,000 | 1.34% |